| Gordon D Reed, MD | |
|
4755 Ogletown Stanton Rd, Newark, DE 19718-2200 | |
| (302) 733-1848 | |
| (302) 733-1848 |
| Full Name | Gordon D Reed |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 38 Years |
| Location | 4755 Ogletown Stanton Rd, Newark, Delaware |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194703918 | NPI | - | NPPES |
| 0000545601 | Medicaid | DE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | C10004277 (Delaware) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Christiana Hospital | Newark, DE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Christiana Care Health Services Inc | 9739097569 | 1248 |
News Archive
Many premature infants suffer a life-threatening destruction of intestinal tissue called necrotizing enterocolitis (NEC). Now a Loyola University Medical Center study has identified a major risk factor for NEC: Preemies with the AB blood type who develop NEC are nearly three times as likely to die from it as preemies with other blood types.
A heavily damaged area of downtown Port-au-Prince and communities in the Southeast province have been assigned to the Pan American Development Foundation and its partners for immediate relief, the non-profit organization announced. www.PanAmericanRelief.org
Although scientists and stock markets have celebrated the approval for emergency use of remdesivir to treat COVID-19, a cure for the disease that has killed nearly 260,000 people remains a long way off — and might never arrive.
In an appearance on "Meet The Press," the outgoing Health and Human Services secretary offered her views on the botched rollout of healthcare.gov and the decision to leave the Obama administration. Meanwhile, news outlets also examine how her resignation unfolded.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
› Verified 2 days ago
| Entity Name | Christiana Care Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770568107 PECOS PAC ID: 9739097569 Enrollment ID: O20031201000477 |
News Archive
Many premature infants suffer a life-threatening destruction of intestinal tissue called necrotizing enterocolitis (NEC). Now a Loyola University Medical Center study has identified a major risk factor for NEC: Preemies with the AB blood type who develop NEC are nearly three times as likely to die from it as preemies with other blood types.
A heavily damaged area of downtown Port-au-Prince and communities in the Southeast province have been assigned to the Pan American Development Foundation and its partners for immediate relief, the non-profit organization announced. www.PanAmericanRelief.org
Although scientists and stock markets have celebrated the approval for emergency use of remdesivir to treat COVID-19, a cure for the disease that has killed nearly 260,000 people remains a long way off — and might never arrive.
In an appearance on "Meet The Press," the outgoing Health and Human Services secretary offered her views on the botched rollout of healthcare.gov and the decision to leave the Obama administration. Meanwhile, news outlets also examine how her resignation unfolded.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
› Verified 2 days ago
| Entity Name | Doctors For Emergency Service |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750369674 PECOS PAC ID: 0648160341 Enrollment ID: O20040317000490 |
News Archive
Many premature infants suffer a life-threatening destruction of intestinal tissue called necrotizing enterocolitis (NEC). Now a Loyola University Medical Center study has identified a major risk factor for NEC: Preemies with the AB blood type who develop NEC are nearly three times as likely to die from it as preemies with other blood types.
A heavily damaged area of downtown Port-au-Prince and communities in the Southeast province have been assigned to the Pan American Development Foundation and its partners for immediate relief, the non-profit organization announced. www.PanAmericanRelief.org
Although scientists and stock markets have celebrated the approval for emergency use of remdesivir to treat COVID-19, a cure for the disease that has killed nearly 260,000 people remains a long way off — and might never arrive.
In an appearance on "Meet The Press," the outgoing Health and Human Services secretary offered her views on the botched rollout of healthcare.gov and the decision to leave the Obama administration. Meanwhile, news outlets also examine how her resignation unfolded.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
› Verified 2 days ago
| Entity Name | Christiana Care Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1245674993 PECOS PAC ID: 9739097569 Enrollment ID: O20130903000474 |
News Archive
Many premature infants suffer a life-threatening destruction of intestinal tissue called necrotizing enterocolitis (NEC). Now a Loyola University Medical Center study has identified a major risk factor for NEC: Preemies with the AB blood type who develop NEC are nearly three times as likely to die from it as preemies with other blood types.
A heavily damaged area of downtown Port-au-Prince and communities in the Southeast province have been assigned to the Pan American Development Foundation and its partners for immediate relief, the non-profit organization announced. www.PanAmericanRelief.org
Although scientists and stock markets have celebrated the approval for emergency use of remdesivir to treat COVID-19, a cure for the disease that has killed nearly 260,000 people remains a long way off — and might never arrive.
In an appearance on "Meet The Press," the outgoing Health and Human Services secretary offered her views on the botched rollout of healthcare.gov and the decision to leave the Obama administration. Meanwhile, news outlets also examine how her resignation unfolded.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
› Verified 2 days ago
| Entity Name | Christiana Care Emergency Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639956451 PECOS PAC ID: 8022468057 Enrollment ID: O20240106000968 |
News Archive
Many premature infants suffer a life-threatening destruction of intestinal tissue called necrotizing enterocolitis (NEC). Now a Loyola University Medical Center study has identified a major risk factor for NEC: Preemies with the AB blood type who develop NEC are nearly three times as likely to die from it as preemies with other blood types.
A heavily damaged area of downtown Port-au-Prince and communities in the Southeast province have been assigned to the Pan American Development Foundation and its partners for immediate relief, the non-profit organization announced. www.PanAmericanRelief.org
Although scientists and stock markets have celebrated the approval for emergency use of remdesivir to treat COVID-19, a cure for the disease that has killed nearly 260,000 people remains a long way off — and might never arrive.
In an appearance on "Meet The Press," the outgoing Health and Human Services secretary offered her views on the botched rollout of healthcare.gov and the decision to leave the Obama administration. Meanwhile, news outlets also examine how her resignation unfolded.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gordon D Reed, MD 4755 Ogletown Stanton Rd, Newark, DE 19718-2200 Ph: (302) 733-1848 | Gordon D Reed, MD 4755 Ogletown Stanton Rd, Newark, DE 19718-2200 Ph: (302) 733-1848 |
News Archive
Many premature infants suffer a life-threatening destruction of intestinal tissue called necrotizing enterocolitis (NEC). Now a Loyola University Medical Center study has identified a major risk factor for NEC: Preemies with the AB blood type who develop NEC are nearly three times as likely to die from it as preemies with other blood types.
A heavily damaged area of downtown Port-au-Prince and communities in the Southeast province have been assigned to the Pan American Development Foundation and its partners for immediate relief, the non-profit organization announced. www.PanAmericanRelief.org
Although scientists and stock markets have celebrated the approval for emergency use of remdesivir to treat COVID-19, a cure for the disease that has killed nearly 260,000 people remains a long way off — and might never arrive.
In an appearance on "Meet The Press," the outgoing Health and Human Services secretary offered her views on the botched rollout of healthcare.gov and the decision to leave the Obama administration. Meanwhile, news outlets also examine how her resignation unfolded.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
› Verified 2 days ago
Dr. Sepehr Sedigh Haghighat, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogletown Stanton Rd, Newark, DE 19718 Phone: 302-733-3901 | |
Paul C Anderson, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogeltown Stanton Road, Newark, DE 19718 Phone: 302-733-1000 Fax: 302-733-1633 | |
Valerie Ann Cohen, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogletown Stanton Rd, Newark, DE 19718 Phone: 302-623-4050 | |
Brian E Burgess, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogletown Stanton Road, Newark, DE 19718 Phone: 302-733-1000 Fax: 302-733-1633 | |
Kristina Louise Stransky, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogletown Stanton Rd, Newark, DE 19718 Phone: 302-733-1042 | |
Dr. John Thomas Powell, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: Christiana Hospital Academic Affairs, Suite 2a00, Newark, DE 19718 Phone: 302-733-1557 | |
Dr. Jennifer Terrano Mink, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogletown Stanton Rd, Christiana Hospital C/o Emergency Medicine Suite 1071, Newark, DE 19718 Phone: 302-733-1840 Fax: 302-733-1633 |